Lilly's GLP-1 Blockbusters Drive 2025 Revenue Surge: What's Ahead?Zacks Investment Research • 02/25/26
Eli Lilly: The Weight‑Loss and Diabetes Powerhouse I'd Hold Through Any Market CrashThe Motley Fool • 02/23/26
Eli Lilly launches new form of obesity drug Zepbound with a month's worth of doses in one penCNBC • 02/23/26
Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPenPRNewsWire • 02/23/26
Novo Nordisk's next obesity drug falls short of Lilly rival, wiping billions off its market valueProactive Investors • 02/23/26
Novo Nordisk Stock Plunges and Eli Lilly Jumps. It's All Down to This Weight-Loss Drug Trial.Barrons • 02/23/26
These Stocks Are Today's Movers: Novo Nordisk, Eli Lilly, Paramount, Nvidia, and MoreBarrons • 02/23/26
Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)PRNewsWire • 02/19/26
Forget Ozempic: This Obesity‑Drug Giant Is Grabbing the Biggest Slice of the GLP‑1 Gold RushThe Motley Fool • 02/19/26
Can LLY's Next-Gen Obesity Pipeline Sustain Growth Amid Competition?Zacks Investment Research • 02/18/26